Cargando…
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
There are approximately 44,000 cases of human papillomavirus–associated (HPV-associated) cancer each year in the United States, most commonly caused by HPV types 16 and 18. Prophylactic vaccines successfully prevent healthy people from acquiring HPV infections via HPV-specific antibodies. In order t...
Autores principales: | Pellom, Samuel T., Smalley Rumfield, Claire, Morillon, Y. Maurice, Roller, Nicholas, Poppe, Lisa K., Brough, Douglas E., Sabzevari, Helen, Schlom, Jeffrey, Jochems, Caroline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119209/ https://www.ncbi.nlm.nih.gov/pubmed/33651712 http://dx.doi.org/10.1172/jci.insight.141912 |
Ejemplares similares
-
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020) -
Therapeutic Vaccines for HPV-Associated Malignancies
por: Smalley Rumfield, Claire, et al.
Publicado: (2020) -
The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020) -
Combination Therapies for HPV-Associated Malignancies
por: Smalley Rumfiled, Claire, et al.
Publicado: (2020) -
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
por: Jochems, Caroline, et al.
Publicado: (2018)